<p>美國主要股指近期因就業數據延遲而回落，失業率高於預期。在這種情況下，投資於便士股票——這一投資領域儘管有些過時，但仍然具有相關性——仍然可以提供獨特的機會。這些股票通常代表較小或較新的公司，當其財務狀況良好時，可以提供價格實惠和增長潛力的結合。讓我們來看看幾隻因財務實力而脱穎而出的有前景的便士股票。</p>
<h3>美國十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國便士股票篩選器的 342 只股票的完整列表。</p>
<p>讓我們回顧一些我們篩選出的顯著股票。</p>
<h2>Cumberland Pharmaceuticals (CPIX)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Cumberland Pharmaceuticals Inc. 是一家專注於醫院急救、胃腸病學和腫瘤學的專科製藥公司，在美國和國際上收購、開發和商業化處方產品，市值為 4442 萬美元。</p>
<p><strong>運營：</strong> 公司的收入完全來自其專科製藥產品，總計 4128 萬美元。</p>
<p><strong>市值：</strong> $44.42M</p>
<p>Cumberland Pharmaceuticals Inc. 的市值為 4442 萬美元，交易價格低於其估計公允價值的 58.4%，這表明在便士股票領域對投資者具有潛在價值。儘管處於虧損狀態，Cumberland 在過去五年中減少了損失，並保持超過三年的正現金流。最近的發展包括與戰略合作伙伴關係共同商業化 Talicia，並擴大 Vibativ 在沙特阿拉伯的市場覆蓋，同時為 Caldolor®注射液獲得 CMS 報銷——這是一種在持續的阿片類藥物危機中提供的非阿片類疼痛管理選擇，突顯了其多元化收入來源和增強財務穩定性的努力。</p>
<ul>
<li>點擊這裏深入瞭解 Cumberland Pharmaceuticals 的具體情況，查看我們的詳細資產負債表健康報告。</li>
<li>通過訪問我們的歷史表現報告，評估 Cumberland Pharmaceuticals 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1c609fa3-4864-418d-8077-1b5fffaa7db6/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1c609fa3-4864-418d-8077-1b5fffaa7db6/chart/debt-equity-history-analysis"/></p>
<p>CPIX 負債與股本歷史及分析截至 2025 年 12 月</p>
<h2>American Well (AMWL)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> American Well Corporation 是一家企業平台和軟件公司，提供數字化混合護理服務，業務遍及美國和國際，市值約為 7547 萬美元。</p>
<p><strong>運營：</strong> 公司的收入來自其互聯網信息提供商部門，總計為 2.6502 億美元。</p>
<p><strong>市值：</strong> $75.47M</p>
<p>American Well Corporation 的市值為 7547 萬美元，運營於數字醫療領域，面臨便士股票典型的挑戰，如虧損和-42.78% 的負股本回報率。儘管如此，它仍保持強勁的財務狀況，短期資產為 2.712 億美元，遠超其短期和長期負債。公司沒有債務，現金流足以支持超過三年的運營，如果當前現金流趨勢持續。最近的指導修訂表明，預計 2025 年的收入將在 2.45 億到 2.48 億美元之間穩定，儘管正在進行運營調整。</p>
<ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解 American Well 的動態。</li>
<li>通過查看我們的增長報告，獲取對 American Well 未來方向的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/91e959b8-d4f4-4dd3-ac2f-fcc215c0ed18/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/91e959b8-d4f4-4dd3-ac2f-fcc215c0ed18/chart/financial-position-analysis"/></p>
<p>AMWL 財務狀況分析截至 2025 年 12 月</p>
<h2>Liquidmetal Technologies (LQMT)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Liquidmetal Technologies, Inc. 是一家材料技術公司，設計、開發和銷售由大宗非晶合金製成的定製產品和零部件，服務於全球各個行業，市值為 9631 萬美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自開發和製造使用非晶合金的產品和應用，總計為 74 萬美元。</p>
<p><strong>市值：</strong> $96.31M</p>
<p>Liquidmetal Technologies, Inc. 的市值為 9631 萬美元，仍處於無收入狀態，收益僅為 74 萬美元。儘管處於虧損狀態，但在過去五年中每年減少損失 13.6%，並保持良好的財務基礎，沒有債務，短期資產為 1490 萬美元，遠超負債。公司報告 2025 年第三季度收入下降至 3.7 萬美元，較去年同期下降，而淨虧損擴大至 55.2 萬美元，反映出在其專注於非晶合金開發的戰略中實現盈利的持續挑戰。</p>
<ul>
<li>點擊這裏瞭解 Liquidmetal Technologies 的細微差別，查看我們的詳細分析財務健康報告。</li>
<li>通過查看我們的歷史業績報告，深入瞭解 Liquidmetal Technologies 的歷史成果。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/051b8377-1d31-4b53-bdb2-47b5eb5301b5/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/051b8377-1d31-4b53-bdb2-47b5eb5301b5/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 12 月 LQMT 的債務與股本歷史及分析</p>
<h2>總結</h2>
<ul>
<li>解鎖更多寶藏！我們的美國便士股票篩選器為您挖掘了 339 家更多公司供您探索。點擊這裏揭開我們精心策劃的 342 家美國便士股票的名單。</li>
<li>尋找替代機會？我們發現 13 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整名單，免費獲取。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>用於國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人機器人，而是能夠在 30 分鐘內在任何地方提供 5G、ISR 和雷達的全自動塔。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>由 CiTech 贊助</p>

AMWL

<p>新聞強調了 Cumberland Pharmaceuticals 作為近期美國經濟形勢下的領先低價股。儘管該公司尚未盈利，但其市值為 4442 萬美元，交易價格低於其估計的公允價值，顯示出潛力。公司在五年內減少了虧損，保持了正現金流，並通過戰略合作伙伴關係擴大市場覆蓋。報告還提到其他有前景的低價股，如 American Well 和 Liquidmetal Technologies，強調了它們的財務健康和增長潛力</p>

<p>Major stock indexes in the United States have recently retreated following delayed jobs data, with unemployment rates higher than anticipated. In this context, investing in penny stocks—an investment area that remains relevant despite being somewhat outdated—can still present unique opportunities. These stocks often represent smaller or newer companies and can offer a blend of affordability and growth potential when backed by strong financials. Let's examine several promising penny stocks that stand out for their financial strength.</p>
<div class="lb-trans"><p>美國主要股指近期因就業數據延遲而回落，失業率高於預期。在這種情況下，投資於便士股票——這一投資領域儘管有些過時，但仍然具有相關性——仍然可以提供獨特的機會。這些股票通常代表較小或較新的公司，當其財務狀況良好時，可以提供價格實惠和增長潛力的結合。讓我們來看看幾隻因財務實力而脱穎而出的有前景的便士股票。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 342 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國便士股票篩選器的 342 只股票的完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>讓我們回顧一些我們篩選出的顯著股票。</p>
</div><h2>Cumberland Pharmaceuticals (CPIX)</h2>
<div class="lb-trans"><h2>Cumberland Pharmaceuticals (CPIX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that acquires, develops, and commercializes prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally, with a market cap of $44.42 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Cumberland Pharmaceuticals Inc. 是一家專注於醫院急救、胃腸病學和腫瘤學的專科製藥公司，在美國和國際上收購、開發和商業化處方產品，市值為 4442 萬美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived entirely from its specialty pharmaceutical products, totaling $41.28 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入完全來自其專科製藥產品，總計 4128 萬美元。</p>
</div><p><strong>Market Cap:</strong> $44.42M</p>
<div class="lb-trans"><p><strong>市值：</strong> $44.42M</p>
</div><p>Cumberland Pharmaceuticals Inc., with a market cap of US$44.42 million, has been trading at 58.4% below its estimated fair value, indicating potential value for investors in the penny stock space. Despite being unprofitable, Cumberland has reduced its losses over the past five years and maintains a positive cash flow runway exceeding three years. Recent developments include strategic partnerships to commercialize Talicia and expand Vibativ's market reach in Saudi Arabia, alongside securing CMS reimbursement for Caldolor® Injection—a non-opioid pain management option amid an ongoing opioid crisis—highlighting efforts to diversify revenue streams and enhance financial stability.</p>
<div class="lb-trans"><p>Cumberland Pharmaceuticals Inc. 的市值為 4442 萬美元，交易價格低於其估計公允價值的 58.4%，這表明在便士股票領域對投資者具有潛在價值。儘管處於虧損狀態，Cumberland 在過去五年中減少了損失，並保持超過三年的正現金流。最近的發展包括與戰略合作伙伴關係共同商業化 Talicia，並擴大 Vibativ 在沙特阿拉伯的市場覆蓋，同時為 Caldolor®注射液獲得 CMS 報銷——這是一種在持續的阿片類藥物危機中提供的非阿片類疼痛管理選擇，突顯了其多元化收入來源和增強財務穩定性的努力。</p>
</div><ul>
<li>Dive into the specifics of Cumberland Pharmaceuticals here with our thorough balance sheet health report.</li>
<li>Evaluate Cumberland Pharmaceuticals' historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Cumberland Pharmaceuticals 的具體情況，查看我們的詳細資產負債表健康報告。</li>
<li>通過訪問我們的歷史表現報告，評估 Cumberland Pharmaceuticals 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1c609fa3-4864-418d-8077-1b5fffaa7db6/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/1c609fa3-4864-418d-8077-1b5fffaa7db6/chart/debt-equity-history-analysis"/></p>
<p>CPIX Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>CPIX 負債與股本歷史及分析截至 2025 年 12 月</p>
</div><h2>American Well (AMWL)</h2>
<div class="lb-trans"><h2>American Well (AMWL)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> American Well Corporation is an enterprise platform and software company that provides digitally enabled hybrid care services in the United States and internationally, with a market cap of approximately $75.47 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> American Well Corporation 是一家企業平台和軟件公司，提供數字化混合護理服務，業務遍及美國和國際，市值約為 7547 萬美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its Internet Information Providers segment, which amounted to $265.02 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入來自其互聯網信息提供商部門，總計為 2.6502 億美元。</p>
</div><p><strong>Market Cap:</strong> $75.47M</p>
<div class="lb-trans"><p><strong>市值：</strong> $75.47M</p>
</div><p>American Well Corporation, with a market cap of US$75.47 million, operates in the digital healthcare sector and faces challenges typical of penny stocks, such as unprofitability and negative return on equity at -42.78%. Despite this, it maintains a strong financial position with short-term assets of US$271.2 million well exceeding both its short- and long-term liabilities. The company has no debt and possesses a cash runway sufficient for over three years if current cash flow trends persist. Recent guidance revisions suggest revenue stabilization between US$245 million to US$248 million for 2025 amidst ongoing operational adjustments.</p>
<div class="lb-trans"><p>American Well Corporation 的市值為 7547 萬美元，運營於數字醫療領域，面臨便士股票典型的挑戰，如虧損和-42.78% 的負股本回報率。儘管如此，它仍保持強勁的財務狀況，短期資產為 2.712 億美元，遠超其短期和長期負債。公司沒有債務，現金流足以支持超過三年的運營，如果當前現金流趨勢持續。最近的指導修訂表明，預計 2025 年的收入將在 2.45 億到 2.48 億美元之間穩定，儘管正在進行運營調整。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of American Well.</li>
<li>Gain insights into American Well's future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解 American Well 的動態。</li>
<li>通過查看我們的增長報告，獲取對 American Well 未來方向的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/91e959b8-d4f4-4dd3-ac2f-fcc215c0ed18/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/91e959b8-d4f4-4dd3-ac2f-fcc215c0ed18/chart/financial-position-analysis"/></p>
<p>AMWL Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>AMWL 財務狀況分析截至 2025 年 12 月</p>
</div><h2>Liquidmetal Technologies (LQMT)</h2>
<div class="lb-trans"><h2>Liquidmetal Technologies (LQMT)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Liquidmetal Technologies, Inc. is a materials technology company that designs, develops, and sells custom products and parts made from bulk amorphous alloys to various industries globally, with a market cap of $96.31 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Liquidmetal Technologies, Inc. 是一家材料技術公司，設計、開發和銷售由大宗非晶合金製成的定製產品和零部件，服務於全球各個行業，市值為 9631 萬美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from developing and manufacturing products and applications using amorphous alloys, totaling $0.74 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自開發和製造使用非晶合金的產品和應用，總計為 74 萬美元。</p>
</div><p><strong>Market Cap:</strong> $96.31M</p>
<div class="lb-trans"><p><strong>市值：</strong> $96.31M</p>
</div><p>Liquidmetal Technologies, Inc., with a market cap of US$96.31 million, remains pre-revenue with earnings of just US$0.74 million. Despite being unprofitable, it has reduced losses by 13.6% annually over the past five years and maintains a solid financial footing with no debt and short-term assets of US$14.9 million surpassing liabilities significantly. The company reported declining revenues for Q3 2025 at US$0.037 million compared to the previous year while net losses widened to US$0.552 million from US$0.441 million, reflecting ongoing challenges in achieving profitability amidst its strategic focus on amorphous alloys development.</p>
<div class="lb-trans"><p>Liquidmetal Technologies, Inc. 的市值為 9631 萬美元，仍處於無收入狀態，收益僅為 74 萬美元。儘管處於虧損狀態，但在過去五年中每年減少損失 13.6%，並保持良好的財務基礎，沒有債務，短期資產為 1490 萬美元，遠超負債。公司報告 2025 年第三季度收入下降至 3.7 萬美元，較去年同期下降，而淨虧損擴大至 55.2 萬美元，反映出在其專注於非晶合金開發的戰略中實現盈利的持續挑戰。</p>
</div><ul>
<li>Click here to discover the nuances of Liquidmetal Technologies with our detailed analytical financial health report.</li>
<li>Gain insights into Liquidmetal Technologies' historical outcomes by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解 Liquidmetal Technologies 的細微差別，查看我們的詳細分析財務健康報告。</li>
<li>通過查看我們的歷史業績報告，深入瞭解 Liquidmetal Technologies 的歷史成果。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/051b8377-1d31-4b53-bdb2-47b5eb5301b5/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/051b8377-1d31-4b53-bdb2-47b5eb5301b5/chart/debt-equity-history-analysis"/></p>
<p>LQMT Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月 LQMT 的債務與股本歷史及分析</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Unlock more gems! Our US Penny Stocks screener has unearthed 339 more companies for you to explore.Click here to unveil our expertly curated list of 342 US Penny Stocks.</li>
<li>Looking For Alternative Opportunities? We've found 13 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖更多寶藏！我們的美國便士股票篩選器為您挖掘了 339 家更多公司供您探索。點擊這裏揭開我們精心策劃的 342 家美國便士股票的名單。</li>
<li>尋找替代機會？我們發現 13 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整名單，免費獲取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用於國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人機器人，而是能夠在 30 分鐘內在任何地方提供 5G、ISR 和雷達的全自動塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 贊助</p>
</div>

坎伯蘭製藥引領 3 只有潛力的便士股